Hypertrophic cardiomyopathy

BJ Maron, MS Maron - The Lancet, 2013 - thelancet.com
Hypertrophic cardiomyopathy is a common inherited cardiovascular disease present in one
in 500 of the general population. It is caused by more than 1400 mutations in 11 or more …

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model

S Wordsworth, J Leal, E Blair, R Legood… - European heart …, 2010 - academic.oup.com
Aims To explore the cost-effectiveness of alternative methods of screening family members
for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and …

HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership …

MJ Ackerman, SG Priori, S Willems, C Berul… - Europace, 2011 - academic.oup.com
1From Mayo Clinic, Rochester, Minnesota; 2Fondazione Salvatore Maugeri University of
Pavia, Pavia, Italy and New York University, New York, New York; 3University Hospital …

Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases

P Elliott, B Andersson, E Arbustini… - European heart …, 2008 - academic.oup.com
In biology, classification systems are used to promote understanding and systematic
discussion through the use of logical groups and hierarchies. In clinical medicine, similar …

Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy

VO Puntmann, T Voigt, Z Chen, M Mayr, R Karim… - JACC: Cardiovascular …, 2013 - jacc.org
Objectives: The aim of this study was to examine the value of native and post-contrast T1
relaxation in the differentiation between healthy and diffusely diseased myocardium in 2 …

Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy

V Nauffal, P Marstrand, L Han, VN Parikh… - European heart …, 2021 - academic.oup.com
Aims Risk stratification algorithms for sudden cardiac death (SCD) in hypertrophic
cardiomyopathy (HCM) and regional differences in clinical practice have evolved over time …

Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter North American registry

SF Nagueh, BM Groves, L Schwartz, KM Smith… - Journal of the American …, 2011 - jacc.org
Objectives: The purpose of the study is to identify the predictors of clinical outcome (mortality
and survival without repeat septal reduction procedures) of alcohol septal ablation for the …

Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy

MS Maron, EJ Rowin, D Lin, E Appelbaum… - Circulation …, 2012 - Am Heart Assoc
Background—In hypertrophic cardiomyopathy (HCM), cardiovascular MR can detect
morphological abnormalities of the left ventricle (LV) not visualized with echocardiography …

Right ventricular involvement in hypertrophic cardiomyopathy

MS Maron, TH Hauser, E Dubrow, TA Horst… - The American journal of …, 2007 - Elsevier
The aim of this study was to assess, using cardiovascular magnetic resonance (CMR),
whether morphologic right ventricular (RV) abnormalities are present in patients with …

Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors

BJ Maron, MS Maron, C Semsarian - Heart rhythm, 2012 - Elsevier
BACKGROUND: Risk stratification strategies employing sarcomere gene mutational
analysis have proved imprecise in identifying high-risk patients with hypertrophic …